(Reuters) – Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
Though still preclinical, PB2452 would likely bolster the safety profile of AstraZeneca’s blood thinner once it reaches the market. https://www.biopharmadive.com/news/astrazeneca-outlicenses-brilinta-reversal-agent/511780/
A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients. http://www.pharmatimes.com/news/eu_oks_low-dose_xarelto_to_prevent_recurrent_vte_1210333
Days before the European Society of Cardiology’s 2017 Congress, the British pharma said an analysis of a prior study showed the drug lowered risk of cardiovascular death. http://www.biopharmadive.com/news/astrazeneca-touts-brilinta-cv-benefit-with-new-analysis/503426/
Merck’s CETP inhibitor anacetrapib and Novartis’ monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category. http://www.mmm-online.com/pipeline/merck-novartis-pipeline-stunners-headline-surprisingly-good-month-for-cv-agents/article/671717/
A Novartis anti-inflammatory drug cut cardiovascular risk for heart attack survivors in a pivotal trial, potentially changing ideas about treatment. http://www.cnbc.com/2017/06/22/novartis-heart-drug-success-opens-up-new-care-option.html
Drugmakers have turned new generation anticoagulants into blockbusters as treatments for strokes and heart attacks, but one area of care where they have made little progress is for treating atrial fibrillation. Cardiology professionals in a new study says that is unfortunate for patients. http://www.fiercepharma.com/pharma/oral-anticoagulants-still-underutilized-afib-study
Teva Pharmaceutical Industries has launched the generic Vytorin (ezetimibe and simvastatin) tablets in the US. http://drugdelivery.pharmaceutical-business-review.com/news/teva-launches-generic-vytorin-in-us-270417-5798304